Figure 5.

Administration of ceramide reverses the protective effects of intestinal HIF-2α inhibition on the development of HFD-induced hepatic steatosis. (a) Representative H&E staining (upper) and Oil Red O staining (lower) of liver sections (n = 5 mice/group, 3 images/mouse). Scale bars, 100 μm. (b) Liver weights. (c) Liver weight–to–body weight ratios. (d,e) Liver (d) and serum (e) triglyceride content. (f,g) Liver (f) and serum (g) cholesterol content. (h) Serum ALT levels. (i) Hepatic expression of mRNAs encoded by hepatic fatty acid transport and lipogenesis-related genes. (j) Hepatic expression of mRNAs encoded by inflammatory cytokine and chemokine genes. Ceramide-treated HFD-fed Hif2a^fl/fl and Hif2a^ΔIE mice. n = 5/group. For box plots, the midline represents the median; box represents the IQR between the first and third quartiles, and whiskers represent the lowest or highest values within 1.5 times IQR from the first or third quartiles. *P < 0.05, **P < 0.01 relative to vehicle-treated Hif2a^fl/fl mice, #P < 0.05, ##P < 0.01 relative to vehicle-treated Hif2a^ΔIE mice, by one-way ANOVA with Tukey’s correction.